FDA Nod to Progenics; Research suggests Curcumin to cure cancer cells

Progenics got FDA Approval; Curcumin to cancer cells

Aug 07, 2018

Progenics got FDA Approval on Iobenguane I 131 for Rare Adrenal Gland Tumors

A good news for unresectable rare adrenal tumor patients as oncologists now have a new treatment to offer . On July 30, 2018, the Food and Drug Administration approved Progenics Pharmaceuticals iobenguane I for adult and pediatric patients with iobenguane scan-positive, unresectable, locally advanced or metastatic pheochromocytoma (PPGL) who require systemic anticancer therapy. Pheochromocytomas are rare tumors of the adrenal glands. The FDA approval of iobenguane I 131 was based on data from a pivotal phase II, open-label, multicenter trial that was conducted under a SPA with the FDA. Iobenguane I 131, is a radiolabeled molecule similar to noradrenaline. Iobenguane I 131 comes with a warning about radiation exposure to patients and family members. The risk of radiation exposure is greater in pediatric patients, according to the FDA.

A new method to deliver herbal supplement curcumin to cancer cells by solving its insolubility has been discoved by the researchers

Curcumin known for its therapeutic effect and as a way to kill germs present in raw meat. It is an effective agent for killing cancer cells.Recently, however, Pan’s laboratory collaborated with Peter Stang on ways to be able to render curcumin soluble, deliver it to infected tumors, and kill cancer cells. The team has created a sophisticated metallocyclic complex using platinum that has not only enabled curcumin’s solubility, but whose synergy has proven 100 times more effective in treating various cancer types such as melanoma and breast cancer cells .They have developed a complex & has a very unique ability to take on different forms of material—from a spherical nanoparticle to longer elongated threads of nanometer size.This drug can be given both orally and intravenously.Even if you are killing all the cells in the tumor, there would be a tiny population of cells with ‘stemness’ properties that could enable cancer cells to grow back and spread to other parts of the body. However, if we can deliver therapy to cancer stem cells, we can prevent that from happening.